XBB.1.5 likely resistant to Evusheld, FDA says
Evusheld, the only authorized COVID-19 preexposure prophylaxis, may not neutralize subvariant XBB.1.5, responsible for nearly 30% of cases, as per FDA. Efficacy against several dominant omicron subvariants remains undetermined. FDA advises healthcare providers to inform patients of increased risk with variants not neutralized by Evusheld.
Reference News
XBB.1.5 likely resistant to Evusheld, FDA says
Evusheld, the only authorized COVID-19 preexposure prophylaxis, may not neutralize subvariant XBB.1.5, responsible for nearly 30% of cases, as per FDA. Efficacy against several dominant omicron subvariants remains undetermined. FDA advises healthcare providers to inform patients of increased risk with variants not neutralized by Evusheld.